Zeneca Limited

Astrazeneca Ab

Astra Zeneca U.k. Limited

John Wall Rayner

Michael J Smithers

Alan Wellington Faull

Andrew G Brewster

Robert J Pearce

Peter W Caulkett

Richard E Shute

Michael Garth Wayne

Stuart D Mills

John Preston

Andrew Stocker

Paul Turner

Darren Mckerrecher

Nowak Thorsten

Sturat D Mills

Compound of formula (I) wherein A is selected from pyridin-2-yl or thiazol-2-yl and R, Rand Rare as described in the specification and their use in the treatment or prevention of a disease or medical conditions mediated through glucokinase. 

Benzofuran derivatives, process for their preparation and intermediates thereof

The invention relates to heterocyclic derivatives of formula (I)A&#x2014;B&#x2014;X&#x2014;T(R)&#x2014;L&#x2014;T(R)&#x2014;X&#x2014;Q&#x2003;&#x2003;(I)or pharmaceutically-acceptable salts thereof, which possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect.

Heterocyclic derivatives

The invention relates to heterocyclic derivatives of formula (I) and (Ia), or pharmaceutically-acceptable salts thereof, which possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect.

Heterocyclic derivatives which inhibit Factor Xa

The invention relates to heterocyclic derivatives of the formula (I): A&mdash;B&mdash;X,&mdash;T,(R,)&mdash;L,&mdash;T,(R,)&mdash;X,&mdash;Q or pharmaceutically acceptable salts thereof, which possess antithrombotic and anticoagulant properties due to their inhibition of Factor Xa and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect.

Heterocycle derivatives which inhibit factor Xa

Compounds of formula I ##STR1## and metabolically labile esters and amides thereof, and pharmaceutically acceptable salts thereof, in which R.sup.13, M.sup.2, X.sup.1, Z.sup.1, Z.sup.1a, X.sup.2 and A.sup.1 have the meanings given in the specification. The compounds are useful as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa. Novel intermediates are also disclosed.

Heterocyclic compounds

Compounds of formula I ##STR1## and metabolically labile esters and amides thereof, and pharmaceutically acceptable salts thereof, in which R.sup.13, M.sup.2, X.sup.1, Z.sup.1, Z.sup.1a, X.sup.2 and A.sup.1 have the meanings given in the specification. The compounds are useful as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa. Intermediates are also disclosed.

Growing community of inventors

Macclesfield, United Kingdom

John Wall Rayner